AllianceBernstein’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.99M Sell
149,327
-6,916
-4% -$165K ﹤0.01% 1648
2025
Q4
$4.17M Buy
156,243
+1,250
+0.8% +$29.9K ﹤0.01% 1626
2025
Q3
$3.31M Sell
154,993
-57
-0% -$1.35K ﹤0.01% 1724
2025
Q2
$3.34M Buy
155,050
+9,770
+7% +$182K ﹤0.01% 1673
2025
Q1
$2.41M Sell
145,280
-2,200
-1% -$40K ﹤0.01% 1797
2024
Q4
$2.71M Hold
147,480
﹤0.01% 1804
2024
Q3
$2.27M Hold
147,480
﹤0.01% 1896
2024
Q2
$2.4M Sell
147,480
-401
-0.3% -$6.47K ﹤0.01% 1843
2024
Q1
$2.73M Buy
147,881
+17,100
+13% +$424K ﹤0.01% 1749
2023
Q4
$4.09M Sell
130,781
-520
-0.4% -$12.4K ﹤0.01% 1578
2023
Q3
$2.74M Sell
131,301
-60,810
-32% -$1.65M ﹤0.01% 1707
2023
Q2
$4.6M Buy
192,111
+39,910
+26% +$887K ﹤0.01% 1459
2023
Q1
$2.86M Sell
152,201
-50,000
-25% -$952K ﹤0.01% 1678
2022
Q4
$3.22M Buy
202,201
+50,000
+33% +$782K ﹤0.01% 1637
2022
Q3
$2.49M Sell
152,201
-17,300
-10% -$280K ﹤0.01% 1741
2022
Q2
$2.39M Buy
169,501
+15,900
+10% +$297K ﹤0.01% 1838
2022
Q1
$3.72M Sell
153,601
-49,649
-24% -$1.2M ﹤0.01% 1730
2021
Q4
$4.74M Sell
203,250
-73,800
-27% -$1.48M ﹤0.01% 1650
2021
Q3
$4.6M Buy
277,050
+122,660
+79% +$2.36M ﹤0.01% 1651
2021
Q2
$3.77M Buy
154,390
+69,561
+82% +$1.57M ﹤0.01% 1793
2021
Q1
$2.19M Sell
84,829
-27,369
-24% -$1.2M ﹤0.01% 2045
2020
Q4
$6M Buy
112,198
+33,299
+42% +$1.65M ﹤0.01% 1389
2020
Q3
$3.25M Sell
78,899
-12,871
-14% -$556K ﹤0.01% 1582
2020
Q2
$4.45M Sell
91,770
-149,999
-62% -$7.2M ﹤0.01% 1387
2020
Q1
$10.2M Sell
241,769
-3,300
-1% -$136K 0.01% 904
2019
Q4
$10.5M Buy
245,069
+30,580
+14% +$1.33M 0.01% 1069
2019
Q3
$7.72M Buy
214,489
+50,790
+31% +$1.54M ﹤0.01% 1155
2019
Q2
$4.38M Buy
163,699
+9,700
+6% +$248K ﹤0.01% 1503
2019
Q1
$4.13M Sell
153,999
-69,741
-31% -$1.63M ﹤0.01% 1480
2018
Q4
$3.62M Buy
223,740
+77,400
+53% +$1.5M ﹤0.01% 1479
2018
Q3
$3.04M Hold
146,340
﹤0.01% 1641
2018
Q2
$2.23M Buy
146,340
+45,744
+45% +$816K ﹤0.01% 1832
2018
Q1
$2.26M Buy
100,596
+2,309
+2% +$63.9K ﹤0.01% 1747
2017
Q4
$2.96M Sell
98,287
-150
-0.2% -$4.8K ﹤0.01% 1578
2017
Q3
$3.71M Sell
98,437
-58
-0.1% -$1.89K ﹤0.01% 1403
2017
Q2
$2.75M Sell
98,495
-30,312
-24% -$903K ﹤0.01% 1612
2017
Q1
$4.43M Sell
128,807
-120
-0.1% -$4.24K ﹤0.01% 1258
2016
Q4
$3.72M Sell
128,927
-443
-0.3% -$11.7K ﹤0.01% 1383
2016
Q3
$4.12M Sell
129,370
-4,900
-4% -$166K ﹤0.01% 1231
2016
Q2
$4.36M Sell
134,270
-50,290
-27% -$1.68M ﹤0.01% 1141
2016
Q1
$5.16M Sell
184,560
-1,356,372
-88% -$29.6M ﹤0.01% 1046
2015
Q4
$54.9M Buy
1,540,932
+128,954
+9% +$4.54M 0.05% 427
2015
Q3
$46.7M Buy
1,411,978
+1,261,578
+839% +$52.5M 0.04% 449
2015
Q2
$6.3M Hold
150,400
0.01% 1024
2015
Q1
$4.9M Buy
150,400
+400
+0.3% +$13.7K ﹤0.01% 1133
2014
Q4
$4.76M Sell
150,000
-3,400
-2% -$96.4K ﹤0.01% 1146
2014
Q3
$3.8M Hold
153,400
﹤0.01% 1235
2014
Q2
$3.46M Sell
153,400
-69
-0% -$1.44K ﹤0.01% 1361
2014
Q1
$3.73M Buy
153,469
+5,753
+4% +$146K ﹤0.01% 1295
2013
Q4
$3.69M Sell
147,716
-6
-0% -$142 ﹤0.01% 1297
2013
Q3
$4.06M Buy
147,722
+13,601
+10% +$284K ﹤0.01% 1186
2013
Q2
$2.43M Buy
+134,121
New +$1.85M ﹤0.01% 1464

Other funds holding ACAD

AllianceBernstein's ACAD Position: Q1 2026 in Review

AllianceBernstein reduced its Acadia Pharmaceuticals (ACAD) stake by 4.4% in Q1 2026, selling an estimated $165K and leaving 149,327 shares worth $3.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1648.

AllianceBernstein first reported a position in ACAD in Q2 2013 and has held it in 52 quarters since. The position peaked at $54.9M in Q4 2015. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • AllianceBernstein held 149,327 shares of Acadia Pharmaceuticals worth $3.99M as of Q1 2026.
  • AllianceBernstein sold 6,916 Acadia Pharmaceuticals shares in Q1 2026, an estimated $165K.
  • Acadia Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #1648 holding.
  • AllianceBernstein first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • AllianceBernstein's Acadia Pharmaceuticals position peaked at $54.9M in Q4 2015.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.